Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Determination of Genetic Predisposition to Patent Ductus Arteriosus in Preterm Infants

View through CrossRef
OBJECTIVE. Patent ductus arteriosus is a common morbidity associated with preterm birth. The incidence of patent ductus arteriosus increases with decreasing gestational age to ∼70% in infants born at 25 weeks' gestation. Our major goal was to determine if genetic risk factors play a role in patent ductus arteriosus seen in preterm infants. METHODOLOGY. We investigated whether single-nucleotide polymorphisms in genes that regulate smooth muscle contraction, xenobiotic detoxification, inflammation, and other processes are markers for persistent patency of ductus arteriosus. Initially, 377 single-nucleotide polymorphisms from 130 genes of interest were evaluated in DNA samples collected from 204 infants with a gestational age of <32 weeks. A family-based association test was performed on genotyping data to evaluate overtransmission of alleles. RESULTS. P values of <.01 were detected for genetic variations found in 7 genes. This prompted additional analysis with an additional set of 162 infants, focusing on the 7 markers with initial P values of <.01, and 1 genetic variant in the angiotensin II type I receptor previously shown to be related to patent ductus arteriosus. Of the initial positive signals, single-nucleotide polymorphisms in the transcription factor AP-2 β and tumor necrosis factor receptor–associated factor 1 genes remained significant. Additional haplotype analysis revealed genetic variations in prostacyclin synthase to be associated with patent ductus arteriosus. An angiotensin II type I receptor polymorphism previously reported to be associated with patent ductus arteriosus after prophylactic indomethacin administration was not associated with the presence of a patent ductus arteriosus in our population. CONCLUSIONS. Overall, our data support a role for genetic variations in transcription factor AP-2 β, tumor necrosis factor receptor–associated factor 1, and prostacyclin synthase in the persistent patency of the ductus arteriosus seen in preterm infants.
Title: Determination of Genetic Predisposition to Patent Ductus Arteriosus in Preterm Infants
Description:
OBJECTIVE.
Patent ductus arteriosus is a common morbidity associated with preterm birth.
The incidence of patent ductus arteriosus increases with decreasing gestational age to ∼70% in infants born at 25 weeks' gestation.
Our major goal was to determine if genetic risk factors play a role in patent ductus arteriosus seen in preterm infants.
METHODOLOGY.
We investigated whether single-nucleotide polymorphisms in genes that regulate smooth muscle contraction, xenobiotic detoxification, inflammation, and other processes are markers for persistent patency of ductus arteriosus.
Initially, 377 single-nucleotide polymorphisms from 130 genes of interest were evaluated in DNA samples collected from 204 infants with a gestational age of <32 weeks.
A family-based association test was performed on genotyping data to evaluate overtransmission of alleles.
RESULTS.
P values of <.
01 were detected for genetic variations found in 7 genes.
This prompted additional analysis with an additional set of 162 infants, focusing on the 7 markers with initial P values of <.
01, and 1 genetic variant in the angiotensin II type I receptor previously shown to be related to patent ductus arteriosus.
Of the initial positive signals, single-nucleotide polymorphisms in the transcription factor AP-2 β and tumor necrosis factor receptor–associated factor 1 genes remained significant.
Additional haplotype analysis revealed genetic variations in prostacyclin synthase to be associated with patent ductus arteriosus.
An angiotensin II type I receptor polymorphism previously reported to be associated with patent ductus arteriosus after prophylactic indomethacin administration was not associated with the presence of a patent ductus arteriosus in our population.
CONCLUSIONS.
Overall, our data support a role for genetic variations in transcription factor AP-2 β, tumor necrosis factor receptor–associated factor 1, and prostacyclin synthase in the persistent patency of the ductus arteriosus seen in preterm infants.

Related Results

Cardiovascular Malformations Among Preterm Infants
Cardiovascular Malformations Among Preterm Infants
Objective. Preterm birth and cardiovascular malformations are the 2 most common causes of neonatal and infant death, but there are no published population-based reports on the rela...
Cerebral artery resistive index in preterm infants and impact of patent ductus arteriosus
Cerebral artery resistive index in preterm infants and impact of patent ductus arteriosus
ABSTRACT Introduction: There is a lack of reference values for the resistive index (RI) of cerebral arteries in preterm infants for our local pop...
Minimal Effective Dose of Indomethacin for the Treatment of Patent Ductus arteriosus in Preterm Infants
Minimal Effective Dose of Indomethacin for the Treatment of Patent Ductus arteriosus in Preterm Infants
The aim of this study was to determine if it was possible to decrease the number of boluses of indomethacin for the treatment of patent ductus arteriosus. This retrospective study ...
Patent as Promise
Patent as Promise
<div> For patent law to serve its purpose of encouraging innovation, would-be inventors must believe that the government will honor its promise to protect their right to exc...
A full-term infant with large patent ductus arteriosus successfully closed with oral ibuprofen: a case report
A full-term infant with large patent ductus arteriosus successfully closed with oral ibuprofen: a case report
Background: Ductus arteriosus is a vascular shunt between the aorta and pulmonary artery. Within the first 24-48 hours of life, the ductus usually closes. Failure of closure is cal...
Echocardiographic Study in Preterm Infant with Hemodynamic Significant Patent Ductus Arteriosus
Echocardiographic Study in Preterm Infant with Hemodynamic Significant Patent Ductus Arteriosus
Background: Potential complications of hemodynamic significant patent ductus arteriosus (hsPDA) after birth include heart failure, need for respiratory support, renal disfunction, ...
Frequency of factors leading to Patent Ductus Arteriosus.
Frequency of factors leading to Patent Ductus Arteriosus.
Background: Patent Ductus Arteriosus is developing as major problem in our society. Many studies in Pakistan has been done to analyze the efficacy of surgical procedures but no one...
Effects of preterm birth and bronchopulmonary dysplasia on infants’ pulmonary function: A cohort study of 117 infants
Effects of preterm birth and bronchopulmonary dysplasia on infants’ pulmonary function: A cohort study of 117 infants
Abstract Background Despite improved preterm infant survival rates in recent years, the increasing prevalence of preterm birth requires ongoing attention to associated ris...

Back to Top